IRVINE, Calif., Dec. 21, 2005 (PRIMEZONE) -- "Recent news announcing a U.S. court ruling that upheld Pfizer's patents and blocked an effort by an Indian pharmaceutical company to launch a generic form of popular cholesterol drug Lipitor are being celebrated in biotech and pharma circles," stated SmallCap Sentinel analyst D.R. Clark. "Provided that the decision weathers an inevitable appeal, Pfizer's billion dollar market should be protected in the U.S. through 2011."
"This is a resounding victory not just for Pfizer, but the pharmaceutical industry," said Clark. "With Lipitor responsible for almost 25 percent of Pfizer's revenues, this issue being resolved should signal safer waters to investors in Pfizer while simultaneously sending a message that the U.S. courts are protective of domestic patents and technology. Company's large and small must be rejoicing."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address a variety of biotech and pharmaceutical related issues for companies including Merck (NYSE:MRK), Pfizer (NYSE:PFE), Glaxosmithkline PLC (NYSE:GSK), and Callisto Pharmaceuticals (AMEX:KAL).
Callisto Pharmaceuticals is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: http://www.trilogy-capital.com/kal_summary.aspx.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.